Biokine Therapeutics is a clinical-stage biopharmaceutical company developing novel drugs to treat cancer. Founded in 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist at Hadassah University Hospital, Biokine has completed many years of R&D and clinical research. The company is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Biokine has developed a suite of unique approaches to target cancer and is conducting preclinical and clinical research on several molecules discovered and developed in-house. The companys lead drug candidate, the high-affinity CXCR4 antagonist BKT140/BL8040, is currently in a phase 2a clinical trial for the treatment of refractory and relapsed acute myeloid leukemia (AML), as well as a phase 1 clinical trial for the mobilization of stem cells. The CXCR4 receptor plays a pivotal role in the regulation of certain cancers and inflammatory diseases and is critically involved in stem cell biology and tissue regeneration. BKT140/BL8040 was licensed to BioLineRx Ltd.